-
Innovation Ranking
NewInnovation Ranking – ALK-Abello AS
ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation, discovers, develops, and commercializes immunotherapies to treat and prevent allergies. The company's allergy immunotherapy product portfolio includes tablets, sublingual or drop-based vaccines, subcutaneous vaccines, and adrenaline auto-injectors to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing ragweed, house dust mite, and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, and...
-
Product Insights
ALK Tyrosine Kinase Receptor – Drugs In Development, 2023
Global Markets Direct’s ALK Tyrosine Kinase Receptor provides in depth analysis on ALK Tyrosine Kinase Receptor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in ALK Tyrosine Kinase...
-
Sector Analysis
ALK Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
ALK Tests Market Report Overview The ALK Tests market size was valued at $27.3 million in 2023. The market is expected to grow at a CAGR of more than 2% during 2023-2033. Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene tests are carried out to detect gene rearrangements within non-small cell lung cancer tumor cells, the outcome of which may guide therapies to treat non-small cell lung cancer (NSCLC). ALK Tests Market Outlook 2023-2023 ($ Million) Buy The Full Report for...
-
Thematic Analysis
NewAutonomous Vehicles in Insurance – Thematic Intelligence
Autonomous Vehicles in Insurance Report Overview The emergence of Level 4 and 5 autonomous vehicles will alter how liability is determined in the motor insurance sector. Countries are updating traffic regulations to consider how self-driving vehicles should be legislated once driver fault is no longer a cause of incidents. Before Level 4 autonomous vehicles become mainstream, vehicles will be increasingly fitted with advanced driver assistance systems (ADAS) such as autonomous emergency braking (AEB) and automated lane-keeping systems (ALKS). Many insurers...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Golidocitinib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golidocitinib in Non-Small Cell Lung Cancer Drug Details: Golidocitinib (DZD-4205)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golidocitinib in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Cutaneous T-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golidocitinib in Cutaneous T-Cell Lymphoma Drug Details: Golidocitinib (DZD-4205) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golidocitinib in Sezary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Sezary Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golidocitinib in Sezary Syndrome Drug Details: Golidocitinib (DZD-4205) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golidocitinib in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golidocitinib in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Golidocitinib (DZD-4205)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alectinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alectinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alectinib in Solid Tumor Drug Details: Alectinib (Alecensa / Alecensaro) is...